| |
Shape the Future of Life Sciences Entries for the Fierce Life Sciences Innovation Awards are coming to a close September 5th, 2024. Submit your entry & lead the charge in life sciences innovation. Enter now! 
|
|
Today’s Big NewsAug 26, 2024 |
|
September 9-12, 2024 | Philadelphia, PA Join us at Digital Pharma East, the leading event for digital innovation in the pharmaceutical industry. Dive into key topics including Digital Marketing, Data & Analytics, and Patient Engagement. Learn from industry experts, network with peers, and explore cutting-edge strategies to drive your digital initiatives forward. The clock is TICKING! Secure Your Pass! .png)
|
|
| By Gabrielle Masson Just days after gene editor Tome Biosciences announced undisclosed operational cuts, a clearer picture is coming into focus as 131 employees are being laid off. |
|
|
|
By Zoey Becker The new rebate model would require eligible hospitals to submit rebate claims after paying full price for the drugs, as opposed to upfront discounts. |
By Heather Landi After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. |
By Nick Paul Taylor Galapagos is coming under additional pressure from investors. Having built a 9.9% stake in Galapagos, EcoR1 Capital is now planning to talk to the Belgian biotech about its performance and the composition of its board. |
|
Thursday, September 12, 2024 | 10am ET / 7am PT Nitrosamines, potent carcinogens, have prompted stringent regulations for their detection and control in various products. With regulatory bodies demanding robust analytical methods and risk assessments, pharmaceutical and medical devices manufacturers must stay on top of the current regulatory landscape and compliance strategies. Register now for access to the key insights you need to know. 
|
|
By Conor Hale Siemens Healthineers aims to grow its PET imaging business by picking up the radiodiagnostic manufacturing and distribution network of Novartis’ Advanced Accelerator Applications division. |
By Kevin Dunleavy Five months after the FDA rejected Regeneron’s bid for accelerated approval of its T-cell engager odronextamab because of the immaturity of its confirmatory trial, the European Union has signed off on the treatment for two types of blood cancers. The European Commission also approved SIFI's first-of-its-kind Akantior for a rare corneal infection disorder. |
By Nick Paul Taylor MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which filed its paperwork weeks after raising $63.5 million privately, is seeking funding to take a would-be challenger to Ascendis Pharma’s rare endocrine disease drug Yorvipath into phase 3 development. |
By Andrea Park A new initiative from the American Optometric Association places the advanced capabilities of the eye on par with those of other highly coveted gadgets, with a goal of educating the public about the power of the eye and encouraging them to prioritize their eye health at least as much as they do their screen time. |
By Fraiser Kansteiner For Lykos Therapeutics and the company’s would-be MDMA-assisted therapy for post-traumatic stress disorder (PTSD), the hits just keep coming. Earlier this month, Lykos was hit by an FDA rejection, research paper retractions and layoffs. Now, the FDA is looking into studies sponsored by the company, The Wall Street Journal reports. |
By Conor Hale Paragonix uses temperature- and pressure-controlled containers to transport heart and lung tissue without causing excess cellular damage, a major upgrade over the traditional ice-filled cooler. |
By Fraiser Kansteiner Belgium’s UCB is selling off its mature neurology and allergy business—plus a manufacturing plant—in mainland China. The deal will see local healthcare asset manager CBC Group and Abu Dhabi-based investment firm Mubadala pay UCB $680 million. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we look at the potential effects of the Chevron overturn on the biopharma industry. |
|
|---|
|
|
|
Wednesday, September 24, 2024 |11am ET / 8am PT In this webinar, we will explore how real-world healthcare data and artificial intelligence can provide key insights into the hidden aspects of patient journeys. Register now. 
|
|
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
